Physician profile
David C Powers
NPI 1215933494
$4,890.37
in general payments reported to CMS, 2019-2025
36 companies · $604 in 2025
The $604 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $454 · 2021: $761 · 2022: $906 · 2023: $828 · 2024: $771 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,203.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,086.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $787.32 | 2020-2025 | |
| Pfizer INC. | $430.18 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.02 | 2019-2025 | Jardiance |
| Amgen INC. | $262.51 | 2019-2024 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.74 | 2020-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $169.18 | 2019-2024 | Airsupra |
| Lilly USA, LLC | $143.99 | 2019-2024 | Jardiance, Emgality, Zepbound |
| Dexcom, INC. | $121.32 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $103.34 | 2019-2025 | |
| Amarin Pharma, INC. | $95.62 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $77.40 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $74.40 | 2022 | |
| Insulet Corporation | $73.14 | 2020 | |
| Sanofi-Aventis U.S. LLC | $65.23 | 2019-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $63.37 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $61.78 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $59.01 | 2024-2025 | Voquezna |
| Abbott Laboratories | $55.83 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $53.25 | 2020-2024 | Shingrix, Arexvy |
| Mylan Specialty L.P. | $49.68 | 2020-2024 | Yupelri |
| Esperion Therapeutics, INC. | $45.47 | 2021 | |
| Corcept Therapeutics | $40.45 | 2025 | Korlym |
| Sunovion Pharmaceuticals INC. | $36.61 | 2020-2021 | |
| Allergan, INC. | $30.12 | 2020 | |
| Ani Pharmaceuticals, INC. | $29.61 | 2025 | Purified Cortrophin Gel |
| Sanofi Pasteur INC. | $29.57 | 2019-2020 | |
| Phadia US INC. | $28.97 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $26.61 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.42 | 2019-2022 | |
| Preventice Services, LLC | $16.48 | 2021 | |
| Inspire Medical Systems, INC. | $14.53 | 2023 | Inspire |
| Lundbeck LLC | $13.20 | 2024 | Rexulti |
| Shire North American Group INC | $11.90 | 2019 | |
| Astellas Pharma US INC | $11.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.